Zoledronic acid (Reclast)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Osteoporosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (3)
US
  • Glucocorticoid-Induced Osteoporosis Reclast is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months [see Clinical Studies ( 14.4 )].
  • Paget's Disease of Bone Reclast is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see Clinical Studies ( 14.5 )].
    Outside this platform's coverage
Product first approved 2007FDA label
EU
  • Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. Treatment of Paget's disease of the bone.
Product first approved 2005EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Osteoporosis
Other / comorbidity
NCT02838121 · Mel Shiuann-Sheng Lee
2009-12 – 2016-06 · Prevention of BMD Loss After THR, Serum Markers of Bone Turnover, Functional Outcomes
What this study did
NCT01348269 · Wuerzburg University Hospital
2011-05 – 2015-08-26 · Bone Marrow Edema
What this study did
NCT00939900 · Seoul National University Bundang Hospital
2009-07 – 2012-06 · Avascular Necrosis of Femoral Head
What this study did
Phase 2 (2)
Osteoporosis
NCT03183557 · Shinshu University
2017-10-12 – 2025-06-08 · Osteoporosis
What this study did
Other / comorbidity
NCT05677152 · AUVA Traumazentrum Vienna Site UKH Meidling
2022-08-22 – 2030-12 · Orthopedics, Traumatology
What this study did
Phase 4 (1)
Other / comorbidity
NCT02333344 · Novartis Pharmaceuticals
2015-07-30 – 2020-01-28 · Prosthetic Fixation After Cementless Total Hip Arthroplasty
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT07056478 · Prince of Wales Hospital, Shatin, Hong Kong
2027-01-01 – 2030-01-01 · Sarcopenia in Elderly
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Osteoporosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zoledronic Acid (Reclast): this drugApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Prolia)ApprovedMonoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic Acid (Zometa)
Approved(overall)
Small moleculeFarnesyl pyrophosphate synthase (FPPS)
not yet graded(overall)
No reviewed efficacy summary in this indication
Zoledronic Acid
Phase 3(overall)
Small moleculeFarnesyl pyrophosphate synthase (FPPS)
not yet graded(overall)
No reviewed efficacy summary in this indication
RT-102DiscontinuedPeptidePTH1 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zoledronic acid (Reclast) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
December 2030 (1)
Phase 2Orthopedics, TraumatologyActive not recruiting
Est. primary completion 2030-12 · NCT05677152 · CT.gov ↗
What to watch

See the full readout calendar ↗